• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.

作者信息

Woo Marcel S, Steins David, Häußler Vivien, Kohsar Matin, Haag Friedrich, Elias-Hamp Birte, Heesen Christoph, Lütgehetmann Marc, Schulze Zur Wiesch Julian, Friese Manuel A

机构信息

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Division of Infectious Diseases, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

J Neurol. 2021 Jan;268(1):5-7. doi: 10.1007/s00415-020-10046-8. Epub 2020 Jul 11.

DOI:10.1007/s00415-020-10046-8
PMID:32654064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7353821/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7909/7815561/371689cd8c9f/415_2020_10046_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7909/7815561/371689cd8c9f/415_2020_10046_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7909/7815561/371689cd8c9f/415_2020_10046_Fig1_HTML.jpg

相似文献

1
Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.利妥昔单抗治疗的神经免疫疾病患者中新型冠状病毒2型感染的控制
J Neurol. 2021 Jan;268(1):5-7. doi: 10.1007/s00415-020-10046-8. Epub 2020 Jul 11.
2
Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.尽管一名水通道蛋白 4 阳性视神经脊髓炎谱系疾病患者存在慢性 B 细胞耗竭，但仍为轻症 COVID-19 感染。
Mult Scler Relat Disord. 2020 Sep;44:102199. doi: 10.1016/j.msard.2020.102199. Epub 2020 May 19.
3
COVID-19 Recovery Without B Cells or Antibodies in Patients Receiving Rituximab for Autoimmune Disease.COVID-19 恢复期患者在接受利妥昔单抗治疗自身免疫性疾病时无 B 细胞或抗体。
Iran J Kidney Dis. 2021 Mar;1(2):159-160.
4
Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis.利妥昔单抗用于复发缓解型多发性硬化急性期的治疗。
Intern Med. 2020 Jan 1;59(1):121-124. doi: 10.2169/internalmedicine.3408-19. Epub 2019 Aug 28.
5
Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.使用维持治疗方案并密切监测 CD19 B 细胞，用利妥昔单抗治疗视神经脊髓炎和视神经脊髓炎谱系障碍。六年随访。
J Neurol Sci. 2017 Jan 15;372:92-96. doi: 10.1016/j.jns.2016.11.016. Epub 2016 Nov 10.
6
Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran.视神经脊髓炎谱系障碍（NMOSD）患者中新型冠状病毒肺炎（COVID-19）感染的评估：来自伊朗的一份报告。
Mult Scler Relat Disord. 2020 Sep;44:102245. doi: 10.1016/j.msard.2020.102245. Epub 2020 Jun 1.
7
Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.利妥昔单抗治疗的视神经脊髓炎谱系障碍患者中的抗JC病毒抗体
J Neurol. 2015 Mar;262(3):696-700. doi: 10.1007/s00415-014-7629-8. Epub 2015 Jan 6.
8
Clinical evaluation of rituximab treatment for neuromyelitis optica.利妥昔单抗治疗视神经脊髓炎的临床评估
Neurologia. 2015 Oct;30(8):461-4. doi: 10.1016/j.nrl.2014.09.001. Epub 2014 Nov 11.
9
Capillary leak syndrome in neuromyelitis optica treated with rituximab.利妥昔单抗治疗视神经脊髓炎中的毛细血管渗漏综合征。
Mult Scler Relat Disord. 2017 Aug;16:22-23. doi: 10.1016/j.msard.2017.06.001. Epub 2017 Jun 6.
10
Rituximab Therapy in Neuromyelitis Optica: Moving Toward a Personalized Medicine Approach.利妥昔单抗治疗视神经脊髓炎：迈向个性化医疗方法
JAMA Neurol. 2015 Sep;72(9):974-7. doi: 10.1001/jamaneurol.2015.1421.

引用本文的文献

1
Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.COVID-19 患者的恢复期血浆治疗伴体液免疫缺陷：连续 3 例病例并文献复习。
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Nov;40(9):507-516. doi: 10.1016/j.eimce.2021.01.009.
2
High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4 T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19.抗 CD20 治疗的 COVID-19 长期患者体内 SARS-CoV-2 特异性 CD4 T 细胞的体外高频率持续存在和表型改变。
Viruses. 2022 Jun 10;14(6):1265. doi: 10.3390/v14061265.
3

本文引用的文献

1
Author Correction: Virological assessment of hospitalized patients with COVID-2019.作者更正：对2019冠状病毒病住院患者的病毒学评估
Nature. 2020 Dec;588(7839):E35. doi: 10.1038/s41586-020-2984-3.
2
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.联合 PD-1、BRAF 和 MEK 抑制治疗晚期 BRAF 突变型黑色素瘤：COMBI-i 的安全性预试验和生物标志物队列。
Nat Med. 2020 Oct;26(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5.
3
An Italian programme for COVID-19 infection in multiple sclerosis.
Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.
特定 T 细胞反应指导 COVID-19 重症患者使用恢复期血浆治疗和体液免疫缺陷：一例报告。
BMC Infect Dis. 2022 Apr 11;22(1):362. doi: 10.1186/s12879-022-07323-4.
4
COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.视神经脊髓炎谱系疾病（NMOSD）患者的 COVID-19 易感性和结局：系统评价和荟萃分析。
Mult Scler Relat Disord. 2022 Jan;57:103359. doi: 10.1016/j.msard.2021.103359. Epub 2021 Nov 1.
5
Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis.抗 CD-20 治疗的多发性硬化症患者 COVID-19 的严重结局：系统评价和荟萃分析。
Mult Scler Relat Disord. 2022 Jan;57:103358. doi: 10.1016/j.msard.2021.103358. Epub 2021 Nov 5.
6
The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review.接受利妥昔单抗治疗的患者感染 COVID-19 的结局：一项叙述性综述。
Iran J Med Sci. 2021 Nov;46(6):411-419. doi: 10.30476/IJMS.2021.88717.1946.
7
Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19.广泛靶向 SARS-CoV-2 的特异性 CD4+ T 细胞反应包括急性和已解决的 COVID-19 患者中经常检测到的膜和核蛋白内的肽特异性。
PLoS Pathog. 2021 Sep 16;17(9):e1009842. doi: 10.1371/journal.ppat.1009842. eCollection 2021 Sep.
8
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
9
Approaching the Interpretation of Discordances in SARS-CoV-2 Testing.解读新型冠状病毒2检测结果不一致的问题
Open Forum Infect Dis. 2021 Mar 23;8(7):ofab144. doi: 10.1093/ofid/ofab144. eCollection 2021 Jul.
10
Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).利妥昔单抗（病毒和机会性感染的风险）的长期安全性。
Curr Rheumatol Rep. 2021 Jul 16;23(9):74. doi: 10.1007/s11926-021-01037-3.
一项针对多发性硬化症患者新冠病毒感染情况的意大利项目。
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
4
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
5
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.利妥昔单抗治疗视神经脊髓炎谱系疾病的安全性和有效性（RIN-1 研究）：一项多中心、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18.
6
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.利妥昔单抗治疗复发缓解型多发性硬化症中的B细胞清除
N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383.